Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while ProShares UltraPro S&P500 trades at $149.15 (market cap $5.68B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| SYRE | UPRO | |
|---|---|---|
Market Cap | $7.35B | $5.68B |
Volume | 1,624,631 | 2,478,701 |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.92 | $157.66 |
52-Week Low | $22.18 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
UPRO trades at $155.38, showing minimal daily movement with a slight decline of 0.05%. The technical picture remains bullish with strong moving average signals, though oscillators suggest neutral momentum. Recent S&P 500 news highlights mixed sentiment with expectations of slowing profit growth alongside potential year-end rallies. The ETF's performance remains tied to broader market dynamics and index composition changes.
Outlook hinges on S&P 500 trajectory with Wall Street projecting potential gains amid valuation concerns. Key risks include market concentration in top holdings and macroeconomic pressures. The absence of fundamental ratios for UPRO requires reliance on underlying index performance and technical indicators for investment decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
